Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]
Discontinued
Reference number: GID-TA10566
Following the announcement that NHS patients will be among first in Europe to benefit from access to ivacaftor, tezacaftor and elexacaftor, the appraisal of this triple therapy is now paused. NICE will work with the company and the NHS on continued data collection to inform a future appraisal. New details and timelines for an appraisal will be confirmed in due course.
https://www.england.nhs.uk/2020/06/nhs-patients-among-first-in-europe-to-benefit-from-landmark-deal-for-cystic-fibrosis-treatment/